Gentian Diagnostics ASA OSL:GENT:
PRIORITIZES REFINEMENT, CAUSING MINOR RUO DELAY
EXPECTS TO PROVIDE AN UPDATE ON RUO PRODUCT DURING Q1 OF 2026
Gentian Diagnostics Says Prioritizes Refinement, Causing Minor Ruo Delay
Gentian Diagnostics ASA on 6ix
Earlier from Gentian Diagnostics
- Gentian Diagnostics presents at the DNB Nordic Healthcare Conference
- Financial calendar
- GENT: Strong Q3 growth driven by U.S. sales and Cystatin C, with robust margins and advancing R&D
- Gentian Diagnostics: Invitation to presentation of third quarter results
- GENT: Q2 revenue up 14% year-over-year; Cystatin C and U.S. sales drive growth despite margin dip
Later from Gentian Diagnostics
- Gentian Diagnostics Enters Exclusive Agreement With Global Diagnostics Company
- Gentian Diagnostics invites to NT-proBNP educational webinar
- Gentian Diagnostics: Invitation to presentation of fourth quarter results
- GENT: Record 2025 sales, strong US growth, new partnership, and NT-proBNP development setback
- Mandatory notification of trade
Follow Gentian Diagnostics into a list and get an email when it puts out news.
Follow Gentian Diagnostics